

# Cost-Effectiveness Analysis of Duodenal–Jejunal Bypass Sleeve Device for People with Obesity

ISPOR 2024
Poster Code: EE13

Qian Xu, Wei Yan, Luo Li, Bao Liu
Department of Health Economics, School of Public Health, Fudan University, Shanghai, China

# Background

- Obesity is a complex chronic disease that has reached epidemic proportions around the world [1,2].
- Lifestyle interventions (diet and physical activities) are the first-line treatment recommended in clinical guidelines<sup>[3-5]</sup>.
- The Duodenal–Jejunal Bypass Sleeve (DJBS, TONGEE®, TONGEE Medical, Hangzhou, China) is a novel nonsurgical device system (Fig 1).

  The DJBS is an impermeable sleeve placed via endoscopy to prevent nutrient absorption in the duodenum and proximal jejunum<sup>[6]</sup>.




Fig 1. TONGEE (Tangji Medical, Hangzhou, China) duodenal–jejunal bypass sleeve device. (a) Sleeve, (b) delivery system, and (c) retrieval system.

# Objective

This study aims to conduct an economic evaluation of

Duodenal—Jejunal Bypass Sleeve (DJBS) plus Intensive Lifestyle

Intervention (ILI) compared with ILI only in people with obesity in

China..

# Methods


- A decision tree Markov model was used to compare 9-month and lifetime horizon cost-effectiveness between DJBS plus ILI and ILI only (Fig 2).
- The data of clinical effectiveness were based on a prospective, open-label and randomized trial (NCT05938231).
- The analysis was performed from the perspective of China's healthcare system. Costs were reported in 2022 Chinese Yuan (CNY ¥).Costs and health outcomes were discounted at an annual rate of 5% [7].

# Methods

- The health outcomes of the analysis were expressed as the difference in body mass index (BMI) from baseline, life years, Quality-Adjusted of Life Years (QALYs), and incremental cost-effectiveness ratio (ICER).
- The Willingness-To-Pay (WTP) ranged from 1~3 times the Gross

  Domestic Product (GDP) per capita in China (GDP per capita ¥85,498,

  2022). The results of the lifetime horizon were presented after half-cycle correction.
- One-way, probabilistic sensitivity and scenario analysis were performed to test the robustness of the results.



#### -----

# Results

- The results of 9-month decision tree model showed that compare to ILI, DJBS plus ILI decreased BMI by 1.69 kg/m<sup>2</sup> (1.41 vs. 3.10), with increasing cost of CNY ¥28,963.98 yuan (CNY ¥29,111.06 vs. CNY ¥147.08). The ICER was CNY ¥17,138.45 yuan per unit decrease of BMI.
- The lifetime horizon model showed that compared to ILI, DJBS plus ILI had a higher cost of CNY ¥13261.94 yuan (CNY ¥ 31,688.98 vs. CNY ¥18,427.04), while with life-years increase of 0.02 (9.43 vs. 9.41) and QALYs increase of 0.15 (7.82 vs. 7.67) per people with obesity. The ICER was CNY ¥88,412.93 per QALY gained.

Table 1 Base case cost-effectiveness results (9 months)

	Total cost(CNY ¥)	Incremental cost (CNY \( \)	BMI	ΔΒΜΙ	ICER (CNY ¥/ΔΒΜΙ)
ILI	147.08	<u>-</u>	1.41	-	- -
DJBS plus ILI	29,111.06	28,963.98	3.10	1.69	17,138.45

Utility decrements among class II obesity
40,694
Discount rate (%)

123,141

Incidence of ALD in obesity (%)

72,542

Utility decrements among class I obesity

74,690

107,623

Utility of T2DM

74,393

104,314

Comorbidities related drug costs (¥)

81,765

107,763

Utility of remission T2DM

82,372

104,377

Remission rate of FLD

76,262

93,599

1CER at lower value of input
1CER at upper value of input
1CER at upper value of input

Fig 3. Tornado Diagram for One-way Sensitivity Analysis

Table 2 Base case cost-effectiveness results (lifetime)

	Total cost (CNY \( \frac{1}{2} \))	Incremental  cost  (CNY \(\frac{1}{2}\))	Total LYs	Increment al LY	Total QALYs	Incrementa 1 QALY	ICER (CNY ¥/LY)	ICER (CNY ¥/QALY)
ILI	18,427.04	-	9.41	-	7.67	-		-
DJBS plus ILI	31,688.98	13,261.94	9.43	0.02	7.82	0.15	663,096.9	88,412.93




Fig 4. The cost-effectiveness planes and cost-effectiveness acceptability curves

# Results

- Sensitivity analysis results
  - The tornado diagram suggested that the utility decrement in class II obesity has the most significance on the ICER (Fig 3).
  - When the WTP threshold is 1 to 3 times GDP per capita, the probability of DJBS plus ILI being cost-effective was 58.4%, 94.2%, and 98.4%, respectively (Fig 4) in Probability sensitivity analysis.
  - ➤ Scenario analysis result showed the ICER was CNY ¥148,218.00 for DJBS plus ILI compared to bariatric surgery.

### Conclusion

Our study showed compared to ILI only, DJBS plus ILI is a costeffective strategy over the lifetime horizon when the WTP threshold was 1.03 times GDP per capita.

# References

- [1] World Obesity Federation, World Obesity Atlas 2023. Available at: https://s3-eu-west-1.amazonaws.com/wof-
- files/World\_Obesity\_Atlas\_2023\_Report.pdf. Accessed 28 Nov 2023.
- [2] Management CMABoH. Acta Nutrimenta Sinica 2021(42):521.
- [3] Branch CNSOPaC. Journal of Xi'an Jiaotong University (Medical Sciences) 2022, 43(4):619-631.
- [4] Grunvald E, et al. Gastroenterology 2022, 163(5):1198-1225.
- [5] Eisenberg D, et al. Surg Obes Relat Dis 2022, 18(12):1345-1356.
- [6] Ren M, et.al. Digestive endoscopy 2023, 35(1):58-66.
- [7] Guoen L,et.al. China Market Press; 2020.

### Contact

- Bao Liu, Professor, E-mail: liub@fudan.edu.cn.
- Qian Xu, PhD student, E-mail: qianxu134@163.com.